BioVie Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIVI Nasdaq 2836 bioviepharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioVie Inc.

BioVie: Long COVID trial fully enrolled – ICYMI - May 29th, 2026 2:30 pm
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - May 29th, 2026 7:00 am
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - May 27th, 2026 6:00 am
BioVie completes enrollment in Long COVID trial as need for treatments grows - May 26th, 2026 11:34 am
BioVie completes enrollment in Phase 2 Long COVID trial - May 26th, 2026 7:12 am
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - May 26th, 2026 6:00 am
BioVie completes final patient visit in Parkinson's drug trial - May 19th, 2026 6:31 am
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease - May 18th, 2026 6:00 am
BioVie CEO shares insights into long COVID trial - ICYMI - May 9th, 2026 7:00 am
BioVie advances long COVID trial, top-line data expected by summer - May 4th, 2026 9:24 am
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 - Apr 27th, 2026 6:00 am
RedChip's Biotech Investor Conference Replays Now Available - Apr 20th, 2026 6:00 am
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting - Apr 14th, 2026 6:00 am
BioVie abstract on Parkinson’s drug accepted for neurology conference - Apr 14th, 2026 3:10 am
BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI - Apr 11th, 2026 5:27 am
BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approach - Apr 9th, 2026 11:44 am
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference - Apr 2nd, 2026 6:45 am
BioVie to present Parkinson’s study data at AD/PD 2026 conference - Mar 12th, 2026 7:05 am
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 - Mar 12th, 2026 6:00 am
60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Feb 27th, 2026 7:00 am